AstraZeneca PLC $AZN Shares Acquired by Arkadios Wealth Advisors

Arkadios Wealth Advisors increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 62.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,205 shares of the company’s stock after purchasing an additional 7,010 shares during the period. Arkadios Wealth Advisors’ holdings in AstraZeneca were worth $1,397,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Chapin Davis Inc. lifted its holdings in shares of AstraZeneca by 3.3% in the 3rd quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock valued at $291,000 after buying an additional 120 shares during the period. CoreCap Advisors LLC raised its position in AstraZeneca by 30.6% in the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after acquiring an additional 125 shares in the last quarter. Highline Wealth Partners LLC lifted its holdings in AstraZeneca by 32.0% in the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after acquiring an additional 129 shares during the period. Aaron Wealth Advisors LLC boosted its position in shares of AstraZeneca by 0.6% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock worth $1,628,000 after purchasing an additional 136 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. grew its stake in shares of AstraZeneca by 4.2% during the 2nd quarter. Pekin Hardy Strauss Inc. now owns 3,650 shares of the company’s stock worth $255,000 after purchasing an additional 148 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wall Street Zen cut shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Jefferies Financial Group assumed coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating for the company. Barclays restated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. TD Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Finally, Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Trading Up 1.4%

Shares of AstraZeneca stock opened at $92.95 on Friday. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $96.51. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. The business has a 50 day moving average price of $91.87 and a 200 day moving average price of $83.50. The company has a market capitalization of $288.31 billion, a P/E ratio of 30.88, a P/E/G ratio of 1.57 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The company had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. During the same quarter last year, the business posted $2.08 earnings per share. AstraZeneca’s revenue was up 12.0% compared to the same quarter last year. Sell-side analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.